This page shows the latest checkpoint inhibitor news and features for those working in and with pharma, biotech and healthcare.
administered selective complement component 5a receptor inhibitor. ... In addition to Tavneos, the acquisition gives Amgen access to three early-stage drug candidates that target chemoattractant receptors in other inflammatory diseases and an oral
The PD-1 inhibitor demonstrated a statistically significant benefit in recurrence-free survival. ... Opdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor, designed to help the natural T-cell response to cancer, by improving the body’s
Opdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor, designed to try to help the natural T-cell response to cancer, by improving the body’s ability to recognise ... In July 2014, Opdivo was the first PD-1 immune checkpoint inhibitor to
doublet chemotherapy and checkpoint inhibitor therapy. ... meeting. "We are grateful to all of the investigators and patients who participated in this first randomised, controlled clinical trial of a KRAS inhibitor.".
Tavneos is an orally administered selective complement component 5a receptor inhibitor. ... As well as Tavneos, ChemoCentryx has three early-stage drug candidates that target chemoattractant receptors in other inflammatory diseases and an oral checkpoint
These include its phase 3 SAR408701 (tusamitamab ravtansine, anti-CEACAM5 antibody-drug conjugate) and its phase 2 SAR444245 (non-alpha IL-2), combining with Tyvyt (sintilimab), the leading checkpoint inhibitor in
More from news
Approximately 11 fully matching, plus 225 partially matching documents found.
Based on the results we have seen with immune checkpoint inhibitors (ICIs), it will be interesting to see how T-DXd performs in the neoadjuvant setting. ... However, the data is very impressive in patients no longer responding to checkpoint inhibitor
Immune checkpoint inhibitors. Immune (T) cells exhibit proteins that can turn an immune response on or off, called checkpoint proteins. ... Several checkpoint inhibitor drugs have been developed showing strong event- free survival and PFS rates, opening
These compounds could be used to tackle resistance to kinase inhibitor drugs, for example. ... The lead project in that partnership is an inhibitor of CBL-B, an immune checkpoint that is still in preclinical development and will migrate to Bristol-Myers
checkpoint inhibitor Imfinzi such as the POSEIDON trial in first-line NSCLC, are key newsflow events this year. ... Trial results for Opdivo alongside CTLA4 checkpoint inhibitor Yervoy (ipilimumab) are one key element of that, particularly better
cells to identify and fight cancer: the PD-1 and PD-L1 checkpoint inhibitor immunotherapies. ... 50%. The true figure for patients treated with checkpoint inhibitor monotherapy achieving durable and meaningful clinical responses is in fact nearer 20%.
More from intelligence
Approximately 0 fully matching, plus 18 partially matching documents found.
This includes the approval of Merck’s checkpoint inhibitor Keytruda (pembrolizumab), which has been approved in over 25 indications across 16 tumour types.
oncology. Prior to Crescendo, Hashimoto (pictured below, right) led the clinical development of a checkpoint inhibitor in renal cell carcinoma at Roche, and held responsibility for multiple.
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
Checkpoint inhibitor-refractory disease represents a growing population and an emerging therapeutic challenge. ... trocar. Further, TAVO has already proven to show robust efficacy in difficult-to-treat patient populations, including metastatic melanoma
Initial findings from small groups of patients suggest CD19-directed CAR T-cell therapy, plus ibrutinib or a checkpoint inhibitor, can enhance responses and/or reduce toxicity in difficult-to-treat
More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.
Accession was a born from a passion and a vision. A passion to harness the power of market access to...